Voyager Therapeutics Restructures Gene Therapy Relationship with Sanofi Genzyme
June 17 2019 - 7:49AM
Dow Jones News
By Michael Dabaie
Voyager Therapeutics Inc. (VYGR) said it restructured its gene
therapy relationship with Sanofi Genzyme.
Voyager said it is gaining worldwide rights to the VY-HTT01
Huntington's disease program and ex-U.S. rights to the VY-FXN01
Friedreich's ataxia program. Voyager is, in turn, transferring the
ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences (NBIX) under
the terms of a collaboration agreement.
Sanofi Genzyme is obtaining exclusive option rights to select
novel AAV capsids owned or controlled by Voyager for exclusive use
for up to two non-central nervous system indications, Voyager
said.
Voyager agreed to make a $10 million upfront payment to Sanofi
Genzyme, which is partially offset by a $5 million payment from
Neurocrine Biosciences to Voyager. An additional $10 million
milestone payment is due to Sanofi Genzyme from Voyager upon filing
of an investigational new drug application for VY-HTT01.
To focus its resources on the now wholly owned Huntington's
disease program, Voyager said it would seek a partner to advance
its preclinical program for SOD1 amyotrophic lateral sclerosis.
Voyager said it no longer expects to file an IND application for
its VY-SOD102 in 2019.
Voyager shares were down 3% to $23.41 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 17, 2019 08:34 ET (12:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (EU:SAN)
Historical Stock Chart
From May 2023 to May 2024